TYRA · NASDAQ · Biotechnology

Tyra Biosciences (TYRA)

Developer of oral FGFR-targeted medicines for urothelial cancers and achondroplasia.

$25.07
After hours−0.48 (−1.90%)
At close$25.56(−0.37%)